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A network model for the determination of tumor metabolic
fluxes from 13C NMR kinetic isotopomer data has been devel-
oped and validated with perfused human DB-1 melanoma cells
carrying the BRAF V600E mutation, which promotes oxidative
metabolism. The model generated in the bonded cumomer for-
malism describes key pathways of tumor intermediary metabo-
lism and yields dynamic curves for positional isotopic enrich-
ment and spin-spin multiplets. Cells attached to microcarrier
beads were perfused with 26 mM [1,6-13C2]glucose under nor-
moxic conditions at 37 °C andmonitored by 13CNMR spectros-
copy. Excellent agreement betweenmodel-predicted and exper-
imentally measured values of the rates of oxygen and glucose
consumption, lactate production, and glutamate pool size vali-
dated the model. ATP production by glycolytic and oxidative
metabolism were compared under hyperglycemic normoxic
conditions; 51% of the energy came from oxidative phosphory-
lation and 49% came from glycolysis. Even though the rate of
glutamine uptake was50% of the tricarboxylic acid cycle flux,
the rate of ATP production from glutamine was essentially zero
(no glutaminolysis). De novo fatty acid production was 6% of
the tricarboxylic acid cycle flux. The oxidative pentose phos-
phate pathway flux was 3.6% of glycolysis, and three non-oxida-
tive pentose phosphate pathway exchange fluxes were calcu-
lated. Mass spectrometry was then used to compare fluxes
through various pathways under hyperglycemic (26 mM) and
euglycemic (5 mM) conditions. Under euglycemic conditions
glutamine uptake doubled, butATPproduction fromglutamine
did not significantly change. A new parameter measuring the
Warburg effect (the ratio of lactate production flux to pyruvate
influx through the mitochondrial pyruvate carrier) was calcu-
lated to be 21, close to upper limit of oxidative metabolism.
Cancer cells exhibit metabolic patterns that differ signifi-
cantly from those of terminally differentiated adult tissues.
They require rapid production of both energy and biosynthetic
precursors to sustain a high rate of proliferation. The network
of biochemical pathways underlying these processes is com-
plex. Most of the individual enzymatic conversions involved in
this network have probably already been identified, but a com-
prehensive and quantitative description of the fluxes involved is
lacking. Methods to produce such descriptions will likely be
very useful in the design of new therapeutics that specifically
target the metabolic abnormalities of cancer as well as in clini-
cal implementation of non-invasive methods for detection of
cancer and its therapeutic response.
The kinetics of 13C isotope labeling as monitored by NMR
spectroscopy has been used to measure flux through various
metabolic pathways of perfused isolated cells and organs and in
vivo (1–4). Kinetic data provide estimates of absolute flux,
whereas steady-state data measure relative flux. Both types of
analysis require validated mathematical models, which have
been formulated for the heart (5–10), liver (11–13), brain (14–
16), and tumors (17). Only the heart model has been validated
by comparison between model-derived and experimental
parameters (6, 7).Modeling of tumormetabolic fluxes has been
limited to steady-state analysis with dynamic measurements of
glucose uptake and lactate production subsequently added to
convert to absolute fluxes; none of these models has been vali-
dated. To the best of our knowledge, this is the first validated
dynamic flux model of tumor intermediary metabolism based
on 13C NMR isotope kinetic data.
Mathematical models of 13C magnetic resonance spectros-
copy data are based on measurement of positional isotopic
enrichment and/or on isotopomer analysis, which takes into
account spin-spin coupling of covalently bonded labeled carbon
atoms.Bondedcumomer analysis includesbothpositional enrich-
ment and isotopomer modeling and facilitates the formulation of
kinetic differential equations. This method requires fewer equa-
tions than classical isotopomer analysis and is based on internal
symmetry properties of metabolite isotopomers.
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Our laboratories have developed a Continuous Stirred Tank
Bioreactor suitable for high resolution 13C NMR spectroscopy
of cultured cancer cells that can produce detailed spectra with
good temporal resolution while simultaneously monitoring the
oxygen consumption rate (18–21). Specifically, we measured
the time course for labeling of key intermediates such as gluta-
mate, aspartate, alanine, lactate, and fatty acyl groups in real
time during growth with 13C-labeled glucose and unlabeled
glutamine as substrates.
Here, we demonstrate that absolute flux measurements of
perfused tumor cells can be obtained in several hours from
5 108 tumor cells in this bioreactor system, and the data can
be analyzed using a refined isotopomer analysis method called
bonded cumomer (BC)3 analysis (22) that utilizes only 210
differential equations to describe most of tumor intermediary
metabolism, whereas the heart model of Chance et al. (5)
required325 differential equations to describe just TCA cycle
activity in terms of positional enrichment. To validate the BC
model, we comparedmodel-derived and experimental values of
the following parameters: O2 consumption rate (MRO2), gluta-
mate pool sizes, as well as rates of glucose consumption and
lactate release. This study permits direct measurements of
energy production by glycolytic and mitochondrial pathways
and quantitative evaluation of the Warburg effect. It also pro-
vides a basis for future studies of the effects of various thera-
peutic interventions on tumor metabolism.Whereas studies of
perfused tumor cells in a bioreactor facilitate accurate and
reproducible measurements, this model is also applicable to in
vivo studies in animal models and humans. Recent studies of ex
vivo surgically resected human brain (23) and lung (24) tumors
point to the potential utility of in vivo 13C MRS clinical
applications.
Experimental Procedures
Cell Culture—DB-1 human melanoma cells were derived
from a lymph node metastasis (Thomas Jefferson University
Hospital, Philadelphia, PA). The cells were obtained before
administration of any treatment. Cells were cultured from the
tumor and cryopreserved after the 16th passage. The presence
of melanoma cell surface antigens was confirmed with mono-
clonal antibodies (25). For routine culture, DB-1 cells were
grown asmonolayers at 37 °C in 5%CO2 in-minimal essential
medium supplemented with 10% fetal bovine serum, 2 mM glu-
tamine, 26 mM glucose, and 1% (v/v) non-essential amino acids
and 10 mM HEPES buffer. The doubling time in tissue culture
flasks was 48 h (26).
Cell Perfusion and NMR Spectroscopy—For cell perfusion
studies, DB-1 cells were cultured in DMEMwith 1% (v/v) non-
essential amino acids (Invitrogen), 10% fetal bovine serum, 10
mM HEPES, 4 mM glutamine, and 26 mM glucose (complete
DMEM).DuringNMRexperiments,5 108 cells were grown
on the surface of non-porous microcarriers that had a mean
diameter of 170 m (SoloHill, Ann Arbor, MI). The surface of
the microcarriers was coated with either collagen or ProNect-
inF to enhance cell attachment and proliferation. The micro-
carriers were tightly packed inside a 20-mm NMR tube. They
were perfused continuouslywith the system shown in Fig. 1A. A
detailed description of the perfusion system, including flow
rates, cell adhesion procedures, etc., has been presented previ-
ously (20).
A peristaltic pump (Masterflex, Cole Parmer, Chicago) was
used to circulate medium through the microcarriers at a flow
rate of 12 ml/min. Before entering the cell mass, the medium
flowed through a gas exchange module where carbon dioxide
was removed, and oxygen was added across a silicone mem-
brane (thin-wall silicone tubing). Subsequently, the medium
was warmed to 40 °C, and the oxygen level was measured con-
tinuously with a polarographic oxygen probe (Mettler-Toledo,
Columbus, OH). The steady-state oxygen level of the medium
at the inlet of the cell mass was maintained near air saturation.
A second polarographic oxygen probe was used to detect the
oxygen level of themediumcoming out of theNMR tube so that
the oxygen consumption rate of the culture could be deter-
mined continuously. A pH probe (Mettler-Toledo, Columbus,
OH)was also used downstream of the outlet oxygen probe. The
pH of the medium was controlled by adjusting the level of CO2
in the gas exchange module. The temperature of the medium
entering the NMR tube was fine-tuned with a microstat-con-
troller and an electrical resistance heater to 37  0.2 °C. The
glucose concentration in the recirculating medium was main-
tained at a constant level (clamped) by continuously feeding
fresh medium and removing depleted medium from a recircu-
lation bottle. The flow rate of fresh medium to the system was
typically 24 ml/h, and the volume of recirculating medium was
120 ml. During the 13C experiments, 32 mM [1,6-13C2]glucose
was introduced into the feed to the system, and the recirculat-
ing glucose level was clamped at 26 mM by adjusting the feed
rate.
13CNMR spectra were acquired with standard 1H decoupled
NOE 13C acquisition on a 9.4 tesla/89 mm vertical bore Varian
spectrometer (Varian Inc., Palo Alto, CA). The acquisition
parameters were as follows: 60° pulse angle, 1.2-s repetition
rate, 25,000Hz spectralwidth, 16,384 points, and 750 transients
per spectrum. To ensure that 1H decoupling did not raise the
temperature of the perfusate above 37.5 °C, the temperature of
the medium leaving the NMR tube was continuously moni-
tored with a thermocouple. Free induction decays were apo-
dized by exponential multiplication (2 Hz) for signal to noise
enhancement. Nuts NMR (Acorn NMR, Fremont, CA) was
used to determine resonance peak areas. The cell number in the
NMR tube was determined from the total NTP level as
described previously (27). 31P spectral parameters were 60°
pulse angle, 1-s repetition rate, 15,000 Hz, and 1200 transients.
In this work, melanoma cells were initially studied under
normoxic hyperglycemic conditions to enhance lactic acidosis
(28, 29) and subsequently under euglycemic conditions tomore
closely simulate in vivo conditions. The effects of glucose con-
3 The abbreviations used are: BC, bonded cumomer; TCA cycle, tricarboxylic
acid cycle; PPP, pentose phosphate pathway; MRO2, O2 consumption rate;
GLUT, glucose transporter;MCT,monocarboxylic acid transporter; FA, fatty
acid; MID, mass isotopomer distribution; G3P, glyceraldehyde 3-phos-
phate; 6PG, D-6-phosphogluconate; Ru5P, D-ribulose 5-phosphate; R5P,
D-ribose 5-phosphate; X5P, D-xylulose 5-phosphate; S7P, D-sedoheptulose
7-phosphate; E4P, D-erythrose 4-phosphate; PDH, pyruvate dehydroge-
nase; MDH, malate dehydrogenase; SDH, succinate dehydrogenase; ADM,
atom distribution matrix; GLS, glutaminase.
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centration on flux through various pathways of tumor metabo-
lism were evaluated. In the initial studies, the concentration of
glucose in the perfusate was maintained at 26 mM, a value that
we believewould be the upper limit for a therapeutic procedure.
In subsequent studies, the glucose concentration was 5 mM.
The kinetics of labeling in lactate, glutamate, and other metab-
olites was monitored over an 6-h time course. The results
were used to estimate intracellular fluxes. The estimated TCA
cycle flux was compared with the oxygen consumption flux to
test the accuracy of the calculations.
Pentose Phosphate Pathway (PPP) Labeling—DB-1 cells were
grown inT-150 flasks in-minimal essentialmedium. At about
70% confluency of cells in the flask, the medium was replaced
with DMEM with 5 mM [1,2-13C]glucose (Cambridge Isotope
Laboratories, Inc., Cambridge, MA) and incubated for 8 h at
37 °C and 5% CO2. The cells were harvested by using 0.05%
trypsin/EDTA (Invitrogen), rinsed twice with phosphate-buff-
ered saline (PBS) at 4 °C, and frozen. The cells were homog-
enized after adding 4 ml of 12 M perchloric acid and were
spun at 13,000 g for 30min. The supernatant was neutralized
with 3MKOH, lyophilized, and dissolved in 0.6ml ofD2O.High
resolution NMR spectra of the metabolites were generated
using a 9.4-tesla spectrometer (Agilent, Palo Alto, CA)
equipped with a 5-mm broadband probe. Proton-decoupled
13C spectra were acquired with the following parameters:
sweep width 20 kHz, number of points 128,000, flip angle
30°, repetition time 7.3 s, and number of average 7000. The
proton-observed carbon-edited NMR technique (30) was
employed to differentiate between the 13C-labeled and -unla-
beled lactate signals in the proton spectra with the following
parameters: sweep width 5 kHz, number of points 32,000,
repetition time 12 s, echo time 1/J 7.8ms, and number of
average  64. Experiments were run in duplicate. iNMR soft-
ware (Mestrelab Research, Spain) was used for spectral fitting
and integration.
Glutaminolysis and Fatty Acids Labeling—DB-1 cells were
grown onC104-1521microcarriers (SoloHill) in uncoatedT-75
flasks with -minimal essential medium. At about 70% conflu-
ency of cells on the microcarrier beads, the medium was
replaced with DMEM with 2 mM L-glutamine (U-13C5, 99%)
(Cambridge Isotope Laboratories, Inc.). Two concentrations of
glucose were used in the medium, 5 and 25 mM. After 8 h of
incubation, the cells were carefully stripped from themicrocar-
riers usingmechanical agitation.Microcarriers were allowed to
settle, and suspension containing cells was collected. Cells were
rinsed twice with PBS at 4 °C and frozen until metabolite
extraction. For fatty acid labeling, cells were grown, incubated,
and harvested as above with the exception that the incubation
was performed for 24 h and the label used was L-glutamine
(13C5, 99%; 15N2, 99%) (Cambridge Isotope Laboratories, Inc.).
LC/MS—The isotope-enriched cells were washed twice with
PBS and resuspended in 700 l of ice-cold methanol. Samples
were pulse-sonicated for 30 s and centrifuged at 16,000 g for
10 min. The supernatant was then transferred to another tube
and evaporated to dryness under nitrogen. Samples were resus-
pended in 100 l of water and analyzed using an Agilent 1200
series HPLC system coupled to an Agilent 6460 triple quadru-
pole mass spectrometer equipped with an ESI source operated
in the negative ionmode. The injection volumewas 10l. Ana-
lytes were separated by reverse-phase ion-pairing chromatog-
raphy utilizing a Phenomenex Luna C18 column (150  2.00
mm, 3 m particle size) at a flow rate of 200 l/min and main-
tained at 45 °C. A two-gradient solvent system was used, with
solvent A as 400 mM 1,1,1,3,3,3-hexafluoro-2-propanol and 10
mM diisopropylethylamine in water, and solvent B as 400 mM
1,1,1,3,3,3-hexafluoro-2-propanol and 10mMdiisopropylethyl-
amine in methanol. The linear gradient conditions were as fol-
lows: 2% B at 0 min; 2% B at 4 min; 95% B at 9 min; 95% B at 11
min; and 2% B at 11.5 min, followed by a 3.5-min equilibration.
TheAgilent 6460mass spectrometer operating conditionswere as
follows: gas temperaturewas set at 320 °C, and the gas flowwas set
to 8 liters/min. The sheath gas temperature was 400 °C, and the
sheath gas flow was set to 10 liters/min. The capillary voltage was
set to 3000 V, and the nozzle voltage was set to 1000 V.
Bonded Cumomer Metabolic Network Model—To calculate
fluxes through key pathways of tumor energy metabolism from
13C isotopic labeling data, we have utilized a novel three-com-
partment metabolic network model with the bionetwork sche-
matically depicted in Fig. 2 and applicable to Continuous
Stirred Tank Bioreactor systems. The model includes medium,
cytosolic and mitochondrial compartments interconnected
with various transporters. The cytosolic membrane contains
glucose (GLUT), monocarboxylic acid (MCT), and glutamine
(GLN) transporters to the cytosolic compartment. Tumors
generally express GLUT1 and GLUT3, but only GLUT1 is cur-
rently included in the model; similarly DB-1 contains MCT1
and MCT4 in approximately equal proportions (26), but
because the Km value of MCT1 is 1/10th that of MCT4, we
have only included MCT1 in the current model. We have
included the GLN transporter (alanine-serine-cysteine (GLN)
transporter 2) because of the critical role of glutamine in tumor
energetics and metabolism. The BC model can readily be
extended to incorporate other isoforms of MCT and GLUT as
well as transporters for other amino acids and metabolites.
The mitochondrial pyruvate carrier, which was recently
identified in all mammalian cells (31–33), was included to per-
mit access of pyruvate to the PDH complex for conversion to
acetyl-CoA and incorporation into the TCA cycle. Pyruvate is
also linked to the TCA cycle via pyruvate carboxylase. Citrate,
glutamate, and malate are included in the cytosolic compart-
ment with direct links through the mitochondria to the TCA
cycle. As already noted, the mitochondrial compartment con-
tains the complete TCA cycle with links to the cytosol for cit-
rate and malate. -Ketoglutarate is linked to glutamate via glu-
tamate dehydrogenase (GLUD) and two aminotransferases,
aspartate aminotransferase (GOT) and alanine aminotrans-
ferase (GPT).
A constructed BC dynamic model adapted to perfusion bio-
reactor experiments was used to fit the 13C time courses of
labeled lactate, glutamate, and fatty acids to determine the cor-
responding metabolic fluxes and the transport parameter for
bidirectional lactate transport through the cell membrane. In
the model, the perfused [1,6-13C2]glucose and glutamine
(labeled in some experiments, see below) are transported from
the extracellular medium to the DB-1 cells assuming that
reversible non-steady-state Michaelis-Menten facilitative
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transport kinetics occurs through glucose (GLUT family) or
glutamine (alanine-serine-cysteine (GLN) transporter 2) trans-













where Jitr is the net transport flux for boundary species i
between media and cytosol or cytosol and mitochondria;Mei
is the extracellular concentration for species i; Jtrmax is the
maximal transport rate; Kmirtr is theMichaelis-Menten constant
for transport. The labeled lactate from the cell is transported
into the medium and obeys the same Michaelis-Menten kinet-
ics through the mono-carboxylic acid transporter (MCT fam-
ily). In this study, facilitatedmedia-cell transport is assumed for
glucose, lactate, and glutamine.
The metabolic network includes glycolysis, TCA cycle, -
ketoglutarate-glutamate, and oxaloacetate-aspartate exchange
through the following: malate-aspartate shuttle; anaplerosis
through (a) pyruvate carboxylase activity, (b) at the succinyl-
CoA level, and (c) glutaminolysis through mitochondrial
glutaminases (GLS and GLS2); pyruvate recycling through
cytosolic (NADP-dependent ME1) and mitochondrial malic
enzymes (NAD-dependent ME2 and NADP-dependent
ME3); lactate dehydrogenase activity; and transport processes.
In this study, PPP fluxes through oxidative and non-oxidative
branches were included in the modeling analysis. The network
also includes de novo lipogenesis and fatty acid oxidation.
The model was expressed mathematically using two types of
mass balance equations, i.e. for chemical and isotope variables.
The mass balance equation for the total metabolite concentra-













whereMi is intracellular concentration of the i species; Jitr is net
transport flux for boundary species ibetweenmedia and cytosol
or cytosol and mitochondria; Fipj and Fiuk are normalized reac-
tion fluxes that produce (j) or utilize (k) cellular species i; and vipj
and iuk are corresponding stoichiometric coefficients. For
extracellular boundary metabolites in the medium, dynamic




 rie  Ji
tr (Eq. 3)
where the extracellular species concentration is Me, and rie is
the ratio of cell volume tomedia volume.An additional term for
the medium flow rate was also was included. Note that we do
not assume here that media boundary metabolites are at con-
stant concentrations, and this assumption (or lack of assump-
tion) is common for bioreactor systems.
Together with the initial metabolome state vector M0  RN
and fluxome Fo  RM (subscript 0 refers to baseline steady-state
values and reaction rates) isotopomer dynamics of this system
are formulated as an initial value problem for ordinary differ-
ential equations in terms of bonded cumomer fractions as the
state variables. For parallel monomolecular reactions, metabo-
lite 13C cumomer mass balance was expressed in the form










where metabolite M is downstream of another metabolite Sj.
The total outflux Fk balances total influx Fj. [M] represents
the total pool size of metaboliteM, whereas 	(i) and 	
j(i) rep-
resent the ith cumomer fraction of metaboliteM and metabo-
lite Sj (i bonded cumomer), respectively.
Isotopomer balance equations were derived for everymetab-
olite bonded cumomer of orders 1, 2, and 3 (e.g. glutamate,
glutamine, and aspartate) as described by Shestov et al. (22).
This resulted in a set of210 differential equations. Fine struc-
ture multiplets were completely described by eachmetabolite’s
bonded cumomers of order 1, 2, and 3. The use of bonded
cumomers leads to a reduced number of equations compared
with a model, including all possible isotopomers, while retain-
ing all theNMR-measurable isotopomer information. The term
cumomer was first proposed by Wiechert et al. (34), and the
concept of cumomer was used in early studies by Muzykantov
and Shestov (35). There are connection matrices between the
“bonded cumomer” 	 vectors, which reflect subsets of particu-
larly labeled isotopomers and the vectors of singlets, doublets,
triplets, and quartets of metabolite “fine structure” of 13CNMR
spectra. One can derive kinetic equations in the form of fine-
structure spectroscopically defined NMR data using matrix
connection equations. For example, for a metabolite with five
carbon atoms such as glutamate, the equation for carbon 2
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For [1,6-13C2]glucose perfusion, the fitted time courses were
as follows: Glu4Tot (Tot-total), Glu4s, Glu4d34, Glu3Tot,
Glu3d, Glu2Tot, Glu2s, Lac3Tot, and acylmethylene (–(CH2)n–)
resonance, for a total of nine curves. The following free fluxes
were determined:melanomaTCAcycle FTCA; pyruvate carbox-
ylase FPC; exchange between glutamate and-ketoglutarate FX;
anaplerotic exchange and net flux at the level of succinyl-CoA;
FANA; mitochondrial malic enzyme (ME2  ME3) activity; de
novo fatty acid production, glutaminolysis, aspartate efflux; and
three other parameters, Michaelis-Menten lactate transport
VmaxLAC, and KmLAC, and total cellular lactate concentration.
Other fluxes and parameters, including the Warburg effect
value, were calculated based on flux balance analysis, including
non-oxidative glycolytic flux CMRlac and others. Solving a sys-
tem of differential equations (using the Runge-Kutta 4th order
procedure for stiff systems) in terms of bonded cumomer vari-
ables yields time courses for all possible fine structure 13Cmul-
tiplets of glutamate, glutamine, and aspartate.
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The classical PPP consists of two branches, irreversible oxi-
dative and reversible non-oxidative parts. The oxidative branch
represents the net PPP flux and produces NADPH, which
can be used in many reductive synthetic pathways, including
de novo lipogenesis. The PPP reactions are summarized in
the Fig. 2.
To describe the pentose phosphate pathway, we used the
steady-state bonded cumomer flux model variant (which re-
sults in a system of non-linear algebraic equations for the 	(i)
cumomer fraction; see the equation for	(i), instead of the set of
differential equations) to fit 13C NMR lactate data acquired
after an 8-h incubation of DB-1 cells with [1,2-13C2]glucose
tracer. The fitted steady-state data were Lac3Tot, Lac2Tot,
Lac3s, Lac3d23, Lac2s, and Lac2d23 multiplets. The relations
between lactate multiplets and bonded cumomers are pre-
sented elsewhere (22). Non-oxidative reactions are assumed
to follow carbon atom redistributions (based on the ping-
pong chemical mechanism) depicted in the following atom
distribution matrices (ADM) (22, 35). Particularly for the
transketolase 1 (TK1) reaction, X5P  R5P N G3P  S7P,
where xylulose 5-phosphate (X5P) and ribose 5-phosphate
(R5P) forms glyceraldehyde 3-phosphate (G3P) and sedo-
heptulose 7-phosphate (S7P), the corresponding ADM is
shown in Matrix 1.
In this matrix the symbol “1” reflects a particular carbon
transfer from substrates (the upper level of the matrix indi-
cates carbon atoms of X5P and the lower level indicates car-
bon atoms of R5P) to products (numbers in the 1st row
reflect carbon atoms of G3P from 1 to 3 and S7P from 1 to 7),
and zero reflects no channeling between particular atoms
in the metabolites. For the transaldolase reaction, S7P 
G3PN E4P  F6P (E4P is erythrose 4-phosphate and F6P is
fructose 6-phosphate), the corresponding ADM is shown in
Matrix 2. Finally, for the transketolase 2 (TK2) reaction,
X5P E4PNG3P F6P, the corresponding ADM is shown
in Matrix 3.
We accounted for the reversibility of every reaction by con-
sidering forward and reverse reaction steps through the non-
oxidative PPP branch with a different extent of reaction revers-
ibility for every reaction above. The system will still result in
constant oxidative PPP net flux for every reaction. Overall,
these matrices show that label at a particular 1st position of
pentose 5-phosphate in the oxidative branch will result in the
labeling of all carbon atoms in downstreammetabolites such as
pyruvate and lactate.
Metabolic and transport parameters as well as metabolite
pool sizes used here are published elsewhere (36). For other
parameters such as concentrations of the TCA cycle interme-
diates not reported in this reference, pool sizeswere assumed to
be in the range 0.1–0.2 mM. The total citrate pool size was
assumed to be 0.5mMwith 20% in themitochondria and 80% in
cytosol. Pyruvate was assumed to be 20% inmitochondria. Sen-
sitivity analysis (not shown here) verified that the chosen TCA
cycle intermediate pool sizes did not affect extracted fluxes
within 5% (even when modified by factors of 5 both above and
below the assumed values).
Minimization of sum-of-squared residuals between simu-
lated and experimental data was performed using Broyden-
Fletcher-Goldfarb-Shanno, Levenberg-Marquardt, or Simplex
algorithms. Propermean square convergencewas confirmed by
verifying that goodness-of-fit valueswere close to expected the-
oretical values. The errors of the calculated parameters were
estimated using Monte Carlo simulations with experimental
noise levels (37). All numerical procedures were carried out in
Matlab (Mathworks, Natick, MA).
In this study, LC-MS data have been utilized to compare
fluxes under different conditions (e.g. hyperglycemia versus
euglycemia) without detailed flux analysis (because no statisti-
cally significant change was observed between the different
medium glucose conditions).
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31P NMR—A typical 31P spectrum is shown in Fig. 1B. The
-NTP resonance at 16.5 ppm was used to estimate the
cell concentration. Other prominent resonances in the spec-
trum are - and -NTP, diphosphodiesters, glycerophospho-
choline, glycerophosphoethanolamine, inorganic phosphate,
phosphocholine, phosphoethanolamine, and diphosphodies-
ters, including NADP(H). A broad hump emanating from
immobilized phosphates from lipids dominates the central
region of the spectrum. This broad peak can be removed by
off-resonance saturation that is mediated by spin diffusion
through the phospholipid semi-immobilized matrix, but this
might modify resonance intensities of metabolites that are par-
tially or transiently bound to membranes (38). We therefore
have avoided off-resonance saturation. Other methods of
removing the “hump” include fitting it with a spline function
and subtracting the base line or subtracting the first spectrum
and monitoring differences in peak intensities over time (39).
The spectrum in Fig. 1B indicates the energy level of the tumor
cells (measured by the intensity of the -NTP peak). The level
was measured before and after the time course of the 13C NMR
experiment and was unchanged. Usually, the bioenergetic sta-
tus of the cells is measured by the -NTP/Pi ratio; however, in a
bioreactor the Pi resonance is dominated by the Pi in the perfu-
sate. The latter peak could be removed by applying strong gra-
dients that dephase resonances of flowing metabolites (38, 40),
but we have not applied this method here because it could lead
to errors if removal of mobile resonances was incomplete.
Metabolic Fate of [1,6-13C2]Glucose in DB-1 Cells—Fig. 2
shows the entire metabolic network that is included in the cur-
rent analysis (see under “Experimental Procedures” for details).
13C labeling results for DB-1 melanoma cells grown at a con-
stant glucose level of 26 mM are shown in Figs. 1C, 3, and 4. Fig.
1C displays a 13C NMR spectrum that was obtained during the
final 15 min of the experiment. Resonances were detected for
C3 of lactate, C2, C3, and C4 of glutamate, C2 and C3 of aspar-
tate, and fatty acyl carbons. With the glucose concentration
clamped at 26mM, lactate labeled at C3 (20.9 ppm) appeared in
the spectrumwithin the first fewminutes (Fig. 4A). The level of
this resonance increased throughout the experiment but did
not reach saturation. The time course of the intensity of this
resonance is the combined result of the biological rate of lactate
formation and the rate of washout of lactate due to the contin-
uous addition of fresh medium and withdrawal of spent
medium from the perfusion system. Fifteenminutes after intro-
duction of labeled glucose, 13C incorporation was detected in
C4 of glutamate (34.3 ppm); the full time course for labeling
results for this resonance is shown in Fig. 3. The concentration
increased in a linear manner for approximately 1 h. Subse-
quently, satellites were observed in this resonance indicating
the presence of 13C-13C coupling between glutamate-C4 and
glutamate-C3 (5). The rate of labeling of glutamate exclusively
on C4 gradually slowed and reached close to steady state after
5 h. The level of glutamate labeled at both C3 and C4 contin-
ued to increase steadily throughout the experiment. Fig. 3, A
and B, shows the labeling results for the glutamate-C3 reso-
nance at 28.8 ppm. Over the 1st h, essentially no 13C labeling
was detected in glutamate-C3. Subsequently, 13C labeling of
glutamate-C3 increased linearly but did not reach saturation.
Approximately two-thirds of theC3 glutamate carbonwas cou-
pled (predominantly to glutamate-C4). For glutamate-C2, label
also first appeared approximately 1 h after the beginning of the
experiment (Fig. 3, A and B). However, unlike glutamate-C3,
only a singlet was observed for the first 3 h. Subsequently, a
doublet appeared due to the presence of glutamate-C2,3 label-
ing. Such glutamate would be produced after carbon 1 was
removed fromglutamate-C3,4 during the third turn of theTCA
cycle (5).
FIGURE 1. Bioreactor design and NMR spectra of DB-1melanoma cells. A,
schematic drawing of the apparatus used to perfuse cells inside the NMR
spectrometer.Twopolarographicoxygenprobesareusedtocontinuallymea-
sure theoxygenconsumption rateof theperfusedculture. Anelectrical resist-
ant heater is used tomaintain the culture at a constant temperature of 37 °C.
The probes and the recirculatedmediumare housed in a small incubator (not
shown) tomaintain the probes at a constant temperature. A peristaltic pump
is used to circulate the medium. Additional details are available in Ref. 20. B,
31P NMR spectrum of metabolically active DB-1 cells. The spectrum was
obtained in 20 min. C, 13C NMR spectrum of metabolically active DB-1 cells
duringperfusionwithmediumcontaining 26mM [1,6-13C2]glucose at the end
of experiment. Glu, glutamate; Lac, lactate; Glc, glucose; std, ethanol in capil-
lary; FA, –CH2– groups in long chain fatty acids.
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Labeling was also observed in long chain fatty acids at 30
ppm, indicating that DB-1 melanoma cells produce lipid de
novo from glucose (see Fig. 4B). This result is consistent with
results for other cancer cell lines grown in culture (19). Small
amounts of labeling were observed in aspartate-C2 and C3. No
label was observed for any carbon of alanine, probably due to
low total concentrations of alanine; this result is unusual
because most cancer cell lines produce 13C-labeled alanine
from glucose (19, 20). Resonances were observed in regions
associated with the glycerol backbone of phospholipids in trig-
lycerides at 65 ppm. This region also contains resonances
associated with glycolytic intermediates.
Quantifying Bionetwork Fluxes—Our biochemical network
model was used to fit 13C NMR DB-1 melanoma data acquired
during continuous perfusion of cells with [1,6-13C2] glucose in
the bioreactor depicted in Fig. 1A. The experimental data from
isotopomer time courses was converted to 13C-metabolite con-
centration curves (Figs. 3 and 4). Furthermore, to minimize the
bias introduced by using multiplets with low signal to noise
ratio, only those multiplets with end point concentrations
greater than 0.5 mM were used in the fitting procedure. The
remaining experimental multiplets were used as reference
points for visually examining the fit predicted for low intensity
curves to experimental data but not actually calculating the
goodness of fit of these metabolite resonances, whose noise
levels were expected to be high (not shown here). To quantify
fluxes in central metabolism, we combined four types of mea-
surements as follows: three sets of time courses of 1) glutamate
isotopomers (multiplets); 2) total lactate-C3 labeling; 3) acyl
groups of fatty acid resonances determined byNMR in situ; and
4) steady-state 13C NMR lactate isotopomers. The fitted time
courses were as follows: Glu4Tot (where Tot is total), Glu4s,
Glu4d34, Glu3Tot, Glu3d, Glu2Tot, Glu2s, Lac3Tot, and acyl
methylene (–(CH2)n–) resonance, yielding a total of nine
curves. Estimation of the model-free parameters was achieved
by fitting labeled patterns of glutamate, lactate, and fatty acid
acyl methylene groups. The extracted flux values are presented
in Table 1 and in the flux map (see Fig. 5). Flux confidence
intervals were calculated by Monte-Carlo simulations (see Fig.
6A, only four fluxes are shown) and are summarized in Table 1.
Quantifying ATP Production Routes—The predicted fluxes
were used to calculate contributions of glycolysis and oxidative
phosphorylation to ATP production.We assumed that the oxi-
dative phosphorylation phosphate to oxygen ratio equals 2.5 for
NADH and 1.5 for FADH2 oxidation. To assess the contribu-
tion of glucose, fatty acids (FA) and glucogenic amino acids, and
glutamine to generating reducing power, we calculated the
fluxes for each of these metabolites. For each of the above sub-
strates, we calculated theNADH/FADH2 reaction flux based on
the different labeling patterns that we were able to track both
FIGURE 2. Melanoma bionetwork: glycolysis, PPP, TCA cycle, -ketoglutarate-glutamate, and oxaloacetate-aspartate exchange through the
malate-aspartate shuttle, anaplerosis through (a) pyruvate carboxylase activity, (b)succinyl-CoA, and (c) glutaminolysis through mitochon-
drial glutaminase (GLS and GLS2); pyruvate recycling through cytosolic (ME1) and mitochondrial malic enzymes (ME2 and ME3), lactate
dehydrogenase activity, de novo fatty acid synthesis, and transport processes. The following abbreviations were used for the metabolites of
glycolysis: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; F16BP, fructose 1,6-bisphosphate; G3P, glyceraldehyde 3-phosphate; PEP, phosphoe-
nolpyruvate. Abbreviations for the oxidative branch of PPP are as follows: 6PG, D-6-phosphogluconate; Ru5P, D-ribulose 5-phosphate. Abbreviations for
the non-oxidative PPP branch are as follows: R5P, D-ribose 5-phosphate; X5P, D-xylulose 5-phosphate; S7P, D-sedoheptulose 7-phosphate; E4P, D-ery-
throse 4-phosphate.
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from the labeled and unlabeled carbon atoms. The combined
cytosolic ATP production flux was 150 mmol/liter-cell/h, and
the mitochondrial compartment produced 154 mmol/liter-
cell/h due to oxidative phosphorylation. The results are pre-
sented in Table 1.
Pentose Phosphate Pathway (PPP)—We fitted 13C NMR
steady-state lactate multiplets acquired after an 8-h incubation
of DB-1 cells with [1,2-13C2]glucose tracer. The experimental
13C NMR spectra and the results of fitting are shown in the Fig.
7. The extracted fluxes relative to glycolytic flux are presented
in Table 1. Flux standard deviations were calculated byMonte-
Carlo calculations. Flux through the oxidative PPP was esti-
mated to be 3.6% of the glycolytic rate. Given the extensive
experimental data that have been obtained for the lactate 13C
NMR multiplets, we were also able to estimate non-oxidative
exchange fluxes (the smaller rates of each reversible reaction) of
the classical PPP (Fig. 2), which are presented in Table 1. Tran-
sketolase 1 and transaldolase exchange fluxes in the non-Ox
PPP branch were consequently relatively high at 21 and 44%,
respectively, and transketolase 2 activity was close to zero. The
flux standard deviations (Table 1) demonstrate that all fluxes
through the PPP were resolved but with relatively poor resolu-
tion (when using only 13C NMR isotopomers of lactate as a
reporter molecule). NADPH production flux via the oxidative
PPP pathway was estimated to be 6.6 mmol/liter-cell/h. At the
end of this experiment, we measured glucose and lactate con-
centration in the flask experiments. Glucose concentrations
under euglycemic conditions were unchanged within 30%.
Quantifying Glutaminolysis Flux—Our recent focus has
turned to refinement of the details of glutaminolysis because of
its critical role in the metabolism of many malignancies. For
example, one glutamine molecule could produce up to 22.5
ATP molecules. Therefore, even a small amount of glutamin-
olysis can have a major effect on the bioenergetics of cancer
cells. In DB-1 melanoma under hyperglycemic conditions, glu-
tamine uptake flux ranged up to 50% of the TCA cycle flux.
FIGURE 3. Time courses for labeling of glutamate during perfusion with
medium containing [1,6-13C2]glucose. A, time course fits for labeling of
glutamate (indicated with “fit” ending) at positions 4, 3, and 2. Glu4, 13C at
glutamate-C4;Glu4s, singlet at glutamate-C4;Glu4d34, doublet at glutamate-
C4; Glu2, 13C enrichment at glutamate-C2; Glu3, 13C at glutamate-C3. “fit”
ending stands for themodel fit andno-ending reflects experimental values.B,
time course for labeling glutamate at positions 2 and 3. Fitted curves labeled
with ending fit are Glu2 and Glu3 total; Glu2s, singlet at glutamate-2; Glu3s,
singlet at glutamate-3;Glu3d, doublet at glutamate-3. PE stands for positional
enrichment; this is predictedmitochondrial enrichmentof acetyl-CoAat posi-
tion C2 and mitochondrial Pyr at position C3 multiplied by a factor of 10.
Curves are fit, and points are experimental data.
FIGURE 4. Experimental data and least squares fit of time course for
labeling of lactate-C3 and fatty acyl methylene (–(CH2)n–) resonance
in proliferating DB-1 melanoma cells during perfusion with medium
containing [1,6-13C2]glucose and unlabeled glutamine. A, time course
for labeling of total lactate-C3 (medium  intracellular). B, de novo lipo-
genesis in melanoma cells. Time course for labeling of fatty acyl methyl-
ene (–(CH2)n–) resonance.
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Under euglycemic conditions, glutamine uptake doubled
reaching approximately the same level as TCA cycle flux. Glu-
tamine uptake can lead to protein synthesis, glutathione syn-
thesis, or nucleotide synthesis as well as to ATP production by
the glutaminolysis pathway (see below) or to cytosolic reductive
carboxylation driven by glutaminase 1 (GLS; it is considered
to be present both in mitochondria and cytosol) or other
glutamine-glutamate conversion enzymes in cytosol and
isocitrate dehydrogenase 1 (IDH1) (41). It was, therefore,
important to refine the metabolic analysis of DB-1 mela-
noma to accurately assess the contributions of the glutami-
nolysis pathway in these tumor cells (see Fig. 2). To quantify
the glutaminolysis contribution to energy production, we
modified the bionetwork by simultaneously allowing net glu-
TABLE 1
Extracted fluxes using bonded cumomer modeling
Reaction Fluxa
mmol/liter-cell/h
Pentose phosphate pathway (oxidative branch), net PPP FpppOx 3.3 72%
Transketolase 1 (exchange) relative to glycolysis, TK1 21 56%
Transketolase 2 (exchange) relative to glycolysis, TK2 0.5 90%
Transaldolase (exchange) relative to glycolysis, TA 44 64%
Glucogenic amino acids contribution to pyruvate, FGAA 5.0 20%
TCA cycle rate, FTCA (isocitrate3 -Kg) 10.9 8%
Exchange, Mal-Asp shuttle, Fx (reversible) 11.3 19%
Pyruvate carboxylase flux, Fpc 0.6 51%
Anaplerotic exchange flux at succinyl-CoA, Fxana 3.0 15%
Net anaplerotic flux to the TCA cycle, dFana 4.3 15%
Flux of ketogenic AA and FA to acetyl-CoA formation, Fkaa 0.1 19%
Glutaminolysis flux, Fgls 0.05 60%
Pyruvate dehydrogenase flux, Fpdh 10.8 16%
Citrate synthase flux, Fcs 11.5 14%
Net fumarase activity, Fum3Mal, Ffum 15.3 16%
Fatty acid synthesis, Ffas 0.59 15%
Mitochondrial pyruvate transport, Fmpc 7.1 23%
Malic enzyme (mitochondrion), ME2ME3, Fmem 4.3 12%
Malic enzyme (cytosolic), ME1, Fmec 0.6 15%
Aspartate efflux, dFxasp 0.06 45%
Production flux of ATP, glycolytic, Warburg, FatpCyt 150 13%
Production flux of ATP, mitochondrial, oxphos, FatpOx 154 12%
Warburg parameter (net LDH/MPC flux ratio) 21 24% (unit-less)
Combined glycolysis and PPP flux from G6P to pyruvate 152.1 12%
Glutamine consumption flux (for protein, nucleotides, amino acids, glutathione, etc.) 4.9 10%b
Net LDH activity, Pyr3 Lac, FLDH 150 12%
Lactate transport, Vmaxlac 395 12%
Lactate transport, Michaelis-Menten parameter, Km 3.5 mM 70%
a Calculated fluxes are expressed in mmol/liter-cell/h with relative standard deviations in percent for pathways shown in Fig. 2. Warburg parameter is the ratio of the net flux
through lactate dehydrogenase (LDH) to the mitochondrial pyruvate carrier influx (MPC).
b Standard deviation was estimated based on experimental measurements of glutamine consumption.
FIGURE 5.Metabolic flux map and energy metabolism with predicted oxygen consumption rate MRO2 in the humanmelanoma DB-1 bionetwork at
hyperglycemia and normoxia. Numbers indicate net fluxes in mmol/liter-cell/h. See Table 1 for definitions and values of the derived fluxes. Reversibility for
SDH, Fumarase, and MDHwas taken into account as 10% of the direct flux. Varying the extent of reversibility in the range 530% does not change extracted
fluxes within several percent (results not shown).
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tamine influx into mitochondria through glutaminase 1 and
2 (GLS and GLS2) (Fig. 2).
“Classical” glutaminolysis includes uptake of glutamine by
the cell, transport to mitochondria, conversion to glutamate
through mitochondrial glutaminase 1 or 2 (GLS and GLS2),
entry into the TCA cycle to -ketoglutarate via glutamate
dehydrogenases 1 and 2 (GLUD1 and GLUD2) or via mito-
chondrial aminotransferases (GPT2 and GOT2), traversing
to oxaloacetate, and exiting as pyruvate or aspartate. Alter-
natively, glutaminolysis could partially occur in the cytosol
by producing glutamate or -ketoglutarate from glutamine
and eventually by entry of those metabolites into the TCA
cycle as -ketoglutarate. Further flux in the TCA cycle then
moves to malate where malate-pyruvate cycling occurs (Fig. 2).
There are two pathways for pyruvate-malate cycling. One path-
way involves conversion of malate via mitochondrial malic
enzyme (ME2) to pyruvate; it then returns to oxaloacetate via
pyruvate carboxylase or it can go from pyruvate to acetyl-CoA
leading to citrate. The second pyruvate cycling pathway goes
frommalate in themitochondria through a transporter into the
cytosol and from there to cytosolic pyruvate via cytosolic malic
enzyme (ME1). The cytosolic pyruvate can return to the mito-
chondria through the mitochondrial pyruvate carrier or it can
be converted to alanine via alanine-aminotransferase (GPT1)
or to lactate via lactate dehydrogenase. The BC approach can
distinguish between these pyruvate-malate pathways or their
combinations under real conditions (Fig. 2).
We continue the analysis of data of DB-1 melanoma cells
treated with [1,6-13C2]glucose as the tracer. Dynamic analysis
indicates that the curves resulting from fitting of theC4-labeled
glutamate multiplets, particularly the glutamate 3,4-doublet,
Glu4d34, resulting from simultaneous labeling of C3 and C4
(during the second TCA cycle turn) and the singlet resulting
from glutamate labeling exclusively at C4 (during the first turn
of the TCA cycle), are very sensitive to flux through the glu-
taminolysis pathway even when only natural abundance me-
dium-derived glutamine has been used. See for example Fig. 6B,
where the separation and shape of the glutamate C4 total and
the glutamate C4 singlet and 3,4-doublet, Glu4d34, curves
FIGURE 6. Confidence intervals revealing the extracted fluxes and the
sensitivity analysis for glutaminolysis pathway.A,MonteCarlo simulation
of relative standard deviations (Rsd) of parameters estimated in fitting of data
in Fig. 3 to the bonded cumomermodel. The experimentally estimated noise
level was 0.2mmol/liter-cell. For example, relative standard deviation for TCA
cycle flux RsdFtca 8%and for pyruvate carboxylase flux RsdFpc 51%. See
Table 1 for definitions and values of the derived fluxes. The red line represents
a Gaussian distribution. Only four fluxes are shown. B, sensitivity analysis for
glutaminolysis pathway during perfusion with medium containing [1,6-
13C2]glucose and unlabeled glutamine. Data show simulated
13C turnover
curves for glutamate C4 (Glu4) and its multiplets 4s and 4d34 for different
values of net glutaminolysis flux Fglswhenglutaminolysis is first set to 20%of
the value of the TCA flux (dashed lines) and then to10% of the TCA flux (solid
lines). The glutamate C2 and C3 multiplets were also sensitive (results not
shown). All other fluxes are kept constant. The glutamate doublet 4d34 is the
most sensitive glutamate multiplet to the glutaminolysis net flux.
FIGURE 7. High resolution 13C and 1H NMR spectra of lactate from DB-1
cells incubated with [1,2-13C2]glucose and experimental lactate multip-
lets versus fit. A, 13C NMR spectra. The left panel shows the NMR spectrum at
the chemical shifts around lactate C2, and the right panel shows the spectrum
around lactate C3. 2s, lactate singlet at C2 position; 2d32, lactate C2 doublet
with carboncouplingbetween thecarbon2and3positions;3s, lactate singlet
from the C3 position; 3d23, lactate C3 doubletwith carbon coupling between
the carbon2and3positions.B,proton-observedcarbon-edited 1HNMRspec-
tra. The upper panel shows the labeled lactate, and the lower panel shows the
unlabeled lactate. C, experimental multiplet fraction (left bars, black) versus
fitting (right bars, patterned) for lactate C3 and C2, and the predicted lactate
C1multiplets, based on the evaluated oxidative and non-oxidative branches
of the PPP. Error bars indicate standarddeviation. The extractedoxidative PPP
flux and the relative exchange fluxes for transketolases and aldolase are pre-
sented in Table 1.
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change dramatically when anaplerotic flux from glutamine
increases from 10% of the TCA flux to 20%. This indicates that
glutamate labeling kinetics is sensitive to glutaminolysis flux
and that there is no need to purchase or synthesize exotically
labeled glutamine (with 13C, 15N, or 2H labeling) to evaluate
glutaminolysis.
We then evaluated the contribution of glutaminolysis flux to
overall energy production of DB-1 melanoma cells. We found
that for this tumor line, glutaminolysis flux through the trun-
cated TCA cycle and via pyruvate-malate cycling by malic
enzyme ME2 is essentially zero. This conclusion resulted
directly from the ability of the model to detect glutaminolysis
flux by fitting of data on the glutamate multiplets (see above).
To further confirm this conclusion, we forced the model to
accommodate glutaminolysis flux between 5 and 20% of the
TCA cycle flux. Invariably, this grossly deteriorated the good-
ness-of-fit of the isotope kinetic data to the model (results not
shown).
Even though glutaminolysis does not contribute to the mito-
chondrial ATP production, there is still substantial mitochon-
drial malic enzyme flux (combined activities of NADH produc-
ingME2 andNADPHproducingME3), which is equal to40%
of the TCA flux (see Table 1).
Effect of Hyperglycemia/Euglycemia on Glutamine and Fatty
AcidMetabolism—Themass isotopomer distribution of several
TCA cycle metabolites from [U-13C5,15N2]glutamine labeling
experiments is shown in Fig. 8 at different glucose concentra-
tions in the medium, at 5 mM for euglycemia and 25 mM for
hyperglycemia. With this tracer, increased glutaminolysis flux
resulted in increased abundance of theM 4mass isotopomer
of citrate, succinate, andmalate (41), whereas reductive carbox-
ylation resulted in increased M 3 for malate, M 4 for suc-
cinate, and M  5 for citrate. Reductive carboxylation and
increased glucose contribution to the fatty acid production also
disturbs the acetyl-CoA mass isotopomer distribution. Fig. 8
clearly shows that there are no significant differences in label-
ing patterns of all four metabolites. Consequently, based on
bioreactor data, we can exclude any major change in glutamin-
olysis flux as well as for fatty acid production under hypergly-
cemic versus euglycemic conditions.
Quantifying de Novo Lipogenesis Flux in DB-1 Cells—During
culturing of DB-1 cells with [1,6-13C2]glucose, progressive
labeling of fatty acids was observed formultiple resonances (see
Figs. 1C and 4B). FA synthesis occurs first by cytosolic citrate
production from glucose and through reductive carboxylation
in the cytosol from glutamine through isocitrate dehydroge-
nase (IDH1 isoform). By ATP citrate lyase, cytosolic citrate is
converted to oxaloacetate and cytosolic acetyl-CoA, which is
converted further to malonyl-CoA by the rate-limiting acetyl-
CoA carboxylase (ACC-) and through fatty acid synthases to
elongated precursors via sequential addition of acetyl-CoA,
eventually leading to palmitate production. Palmitate is fur-
ther elongated or desaturated to produce numerous other
FAs. To address de novo FA flux production, we utilized the
BC model with cytosolic FA and their precursors as well as
membrane fatty acids as the second FA pool. We calculated
FA content based on the total FA content of20% of cell dry
weight of 200 mg/109 cells (5  108 cells  1 ml). Total FA
content referenced to palmitate is at the level of several tens
of mmol/liter-cell. We iteratively varied the ratio of cytosolic
tomembrane FA and found the best fit at10 timesmore FA
in the cytosolic membrane compartment (Fig. 4B). The de
novo flux of conversion of glucose to FAwas 0.59mmol/liter-
cell/h, and NADPH consumption flux in FA biosynthesis was
8.4 mmol/liter-cell/h.
Model Validation—As validation of the inferred/extracted
fluxes, we measured the MRO2 with polarographic oxygen
probes during the perfusion experiment. The fluxes obtained
by fitting of dynamic 13C data produced good agreement
between the experimentally observed MRO2, 33 mmol/liter-
cell/h, and the calculated MRO2, 32 mmol/liter-cell/h (see
Table 2). The experimental total glutamate concentration was
8.6 mM. Assuming the glutamate concentration to be a fitted
FIGURE 8. Mass isotopomer distribution for the TCA cycle intermediate
and acetyl-CoA measured at hyperglycemic and euglycemic conditions
during [U-13C5]glutamine labeling. Mass isotopomer distribution (MID) of
A, citrate; B, malate; C, succinate; and D, acetyl-CoA. The figure clearly dem-
onstrates that there are no significant differences in labeling patterns of key
metabolites (p value was always 0.05) between 5 mM glucose and 25 mM
medium glucose conditions.
TABLE 2
Experimental data compared with calculated values determined by
dynamic bonded cumomer modeling






Oxygen consumption, MRO2 33 32
Glucose uptake, MRGlc 90.0 78a
LDH activity, Pyr3 Lac, Fldh 155.0 150
Glutamine uptake, FGln 5.0 –b
Glutamate concentration 8.6c 9.2
a The difference between experimental and calculated glucose consumption rates
is due to glycogen production that is not included in the metabolic network
model.
b The flux was not estimated since glutamine is consumed in numerous reactions
that were not included in the analysis.
c The glutamate concentration was measured at the end of the bioreactor experi-
ment by cell extraction and LC-MS analysis.
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parameter, we calculated this parameter and obtained a value of
9.2 mM in good agreement with the experimental concentra-
tion. The measured glucose consumption rate (MRGlc) was 90
mmol/liter-cell/h, whereas the predicted MRGlc was 78 mmol/
liter-cell/h. Simultaneously, the measured lactate production
flux (MRlac) was 155 mmol/liter-cell/h, whereas the predicted
MRlac was 150. We note that we did not use experimentally
measured fluxes as constraints in our bonded cumomer meta-
bolic flux analysis.
Table 3 compares glucose and glutamine uptake under eug-
lycemic (6mM glucose) and hyperglycemic (23mM) conditions.
Under euglycemic conditions, glutamine influx approximately
doubles, whereas glucose consumption remains essentially
unchanged. Table 4 shows the glucose and lactate concentra-
tions at the end of experiments at different glycemic conditions
conducted in the flaskexperiments formass spectrometricmea-
surements. Glucose concentrations were unchanged within
30% under euglycemic conditions and within 5% under hyper-
glycemic conditions. Finally, we were able to generate a flux
map (Fig. 5). This figure shows the extracted metabolic fluxes
with the predicted MRO2. Numbers indicate fluxes in mmol/
liter-cell/h. See Table 1 for definitions and values of the derived
fluxes.
Discussion
Measuring the relative glycolytic and oxidative capacity of
specific tumors plays an important role in development of strat-
egies for treating neoplasms and for monitoring tumor re-
sponse to specific therapeutic agents. For this reason, develop-
ment of a non-invasive method for quantifying the fraction of
ATP production by tumors that occurs by glycolytic and
mitochondrial metabolism would be useful in the manage-
ment of cancer and tailor-fitting of therapeutic regimens to
the needs of individual patients. In addition, various other
pathways of tumor metabolism play critical roles in tumor
proliferation by providing additional energy sources and
essential precursors for cell replication. Our goal was to
develop a method for quantitating tumor intermediary
metabolism in cells and with some extension in animal
tumor models and human cancer patients.
One of our key objectives was to validate the bonded
cumomer modeling technique as a method for measuring
fluxes through key pathways of tumor energy production. This
is best accomplished by comparing model predicted parame-
ters with independently measured experimental parameters as
has been demonstrated previously by Chatham et al. (6) for the
cardiacTCAcyclemodel ofChance et al. (5) and Jeffrey et al. (7)
for the isotopomer model of the heart. Table 2 compares mod-
el-predicted and experimentally measured parameters. There
is excellent agreement between the predictedMRO2 (32mmol/
liter-cell/h) and the experimentally measured rate of oxygen
consumption (36 mmol/liter-cell/h). The experimental and
predicted rates of glucose uptake agree within 7%. The experi-
mental and predicted pyruvate to lactate fluxes, 149 and 150,
respectively, agree within1% and glutamate pool sizes within
7%.Overall, this excellent agreement betweenmodel-predicted
and experimental data validates the BC model.
ATP production fluxes were calculated assuming a phos-
phate to oxygen ratio of 2.5 for NADH and 1.5 for FADH2 (42).
Under hyperglycemic conditions, the average ATP production
rates were MRATP (mitochondrial)  154 mmol/liter-cell/h
and MRATP (glycolytic)  150 mmol/liter-cell/h which indi-
cates that 51% of the energy was produced by oxidative phos-
phorylation and 49% was from glycolysis. Based on the similar-
ity of isotopomer labeling patterns under hyperglycemic and
euglycemic conditions (Fig. 8), we expect no significant change
in glycolytic and oxidative metabolism under these conditions.
High fluxes of pyruvate mitochondrial transport (70% of the
TCA cycle activity) and mitochondrial ATP production are
promoted by themelanoma-associatedBRAFmutation. Recent
work (43) has demonstrated that BRAF V600E mutated mela-
noma cells exhibit increased pyruvate entry through the acti-
vated PDH complex. PDH flux (106% of the TCA flux) is
regulated by inhibitory phosphorylation mediated by PDH
kinases (PDK) and PDH phosphatases (PDP). The oncogene
BRAF V600E causes concerted activation of the PDH complex
by down-regulation of PDK1 expression and up-regulation of
PDP2 thereby promoting oxidative pyruvate utilization and
leading to increased cellular respiration.
There has been considerable interest in glutamine metabo-
lism as a key source of tumor energy production linked to
c-Myc expression (21, 44–47). Our model of tumor metabo-
lism (Fig. 2) contains a specific glutamine transporter on the cell
membrane. The classical model of glutaminolysis includes an
additional specific glutamine transporter on the mitochondrial
membrane that leads to mitochondrial glutaminase (GLS2 or
GLS), which converts glutamine to glutamate, which is then
converted to -ketoglutarate by enzymes such as glutamate de-
hydrogenase (GLUD1 and -2). Two additional transaminases
can carry out the glutamate–-ketoglutarate exchange, aspar-
tate aminotransferase, and alanine aminotransferase. The -
ketoglutarate then produces reducing equivalents via the oxi-
dative branch of the TCA cycle leading to ATP production by
oxidative phosphorylation. Various pathways, including the
malate-aspartate shuttle, pyruvate carboxylase, malic enzyme,
and phosphoenolpyruvate carboxykinase (PEPCK1 and -2) all
TABLE 3
Experimental glucose and glutamine consumption fluxes under
euglycemic (6.4 mM) and hyperglycemic conditions (23.2 mM in
medium)
Glutamine 3.0mMat lowglucose and 3.4mMat high glucose. FGlc, glucose consump-
tion flux (mmol/109cells/h) and FGln, glutamine consumption (mmol/109cells/h). Flux





Euglycemia (6.4 mM) 0.064 0.86
Hyperglycemia (23.2 mM) 0.035 0.79
TABLE 4
Experimental medium glucose and lactate concentrations under
euglycemic (5.1 mM glucose in medium) and hyperglycemic condi-





Euglycemia (5.1 mM) 3.6 0.1 5.0 0.2
Hyperglycemia (25.0 mM) 23.4 0.1 5.5 0.3
a Initial medium lactate concentration was 1.8 mM for euglycemic conditions and
2.0 mM for hyperglycemia.
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contribute to metabolism of the glutamine carbon atoms. As
noted previously, glutaminemetabolism can lead to production
of 22.5molecules of ATP per glutaminemolecule. In the case of
DB-1 melanoma cells under hyperglycemic conditions, gluta-
mine influx constituted about 50% of the TCA cycle flux, with
about double this level of glutamine uptake under euglycemic
conditions (Table 3). However, the transaminase reactions are
reversible and may exhibit high exchange flux in both direc-
tions even with very little net glutamine uptake by the TCA
cycle and nearly no energy production from the glutaminolysis
pathway in DB-1 cells. It is important to note that because car-
bon atoms of glutamate originating from glucose will be isoto-
pically labeled (first onC4 position and then onC2 andC3 etc.),
whereas carbons coming from glutamine will be unlabeled, it
was possible to distinguish the two pools of carbon atoms orig-
inating from these two substrates. The data fitting clearly indi-
cated that the net flux from glutamine being metabolized via
the TCA cycle was very small.
We also conducted a sensitivity analysis to show that using
[1,6-13C2]glucose tracer alone suffices to reliably calculate
glutaminolysis flux in malignant cells and tissues. Fig. 6B
shows that the glutamate C4 doublets due to C3-C4 coupling
(Glu4d34) are sensitive to net flux of unlabeled glutamine
entering the TCA cycle; even a 10% difference in flux produces
a clearly detectable shift in these curves. Fitting analysis indi-
cated that there was little net influx from glutamine into the
TCA cycle. Note also that this conclusion can also be reached
from 13C NMR data without the use of labeled glutamine.
By contrast, some investigators utilizing mass spectrometry
have equated glutamine uptake minus glutamate release with
net glutaminolysis flux (48). In this case, the net influx of gluta-
mine is 5 mmol/liter-cell/h, which, if it were equated with
glutaminolysis flux, would have been interpreted as 113 mmol/
liter-cell/h of ATP per h or about 75% of the glycolytic produc-
tion of ATP. Under euglycemic conditions, which produce
about twice the level of glutamine uptake, such an analysis
would have attributed about 50% higher ATP production to
glutaminolysis than to glycolysis, andmost of the tumor energy
production would have been attributed to glutaminolysis. This
is incorrect in our case; in reality the net glutaminolysis flux
under hyperglycemic conditions is 0.1 mmol/liter-cell/h or
2 mmol of ATP/liter-cell/h or 1% of the glycolytic ATP
production rate. Bonded cumomer analysis provides a method
for making this crucial distinction. Our labeled LC-MS data for
the TCA cycle intermediates with [U-13C5,U-15N2] glutamine
confirmed that no glutaminolysis occurred under euglycemic
conditions versushyperglycemia (Fig. 8). The absence of change
in glutaminolysis or reductive carboxylation flux is evident
from similar mass isotopomer distributions of several key
metabolites. Our finding of nearly zero glutaminolysis flux con-
tradicts Scott et al. (49), who, on the basis of glutamine uptake
and label appearance in some TCA cycle metabolites, con-
cluded that glutamine was utilized as an anaplerotic substrate
of several human melanoma lines. However, these authors did
not conduct a rigorousmetabolicmodeling analysis tomeasure
flux through the TCA cycle. Consequently, they were unable to
distinguish between actual flux through the cycle via glutamin-
olysis and exchange labeling between -ketoglutarate and glu-
tamate without any net flux. In addition, glutamine could be
used for many other metabolic processes besides energy pro-
duction, e.g. protein, nucleotide, and hexosamine synthesis.
If the net uptake of glutamine is 5 mmol/liter-cell/h with
negligible contribution to energy production, glutamine must
be contributing primarily to anabolic processes such as amino
acid, nucleotide, and protein production as well as to de novo
lipogenesis. Although glutamine-derived carbons have been
unlabeled, we have monitored lipogenesis by 13C NMR
detecting methylene carbon acyl groups originating from
labeled glucose (Figs. 1C and 4B). Table 1 indicates that de
novo lipogenesis corresponds to 6% of the TCA cycle flux
under hyperglycemic conditions. However, this does not
include possible direct contributions from unlabeled gluta-
mine (i.e. through cytosolic reductive carboxylation by isoci-
trate dehydrogenase IDH1 or mitochondrial IDH2) and
potentially from the cytosolic acetyl-CoA synthetase 2
(ACSS2) reaction (50).
This modest flux for de novo fatty acid synthesis requires a
large contribution of NADPH cofactor production (8.3
mmol/liter-cell/h).NADPHcould be produced by the oxidative
branch of the PPP, malic enzyme, or isocitrate dehydrogenase
activities or by serine-glycine one-carbon metabolism (folate
metabolism). Our calculated malic enzyme activities in mito-
chondria (even if all this activity is represented by ME3) would
account for 4.3 mmol/liter-cell/h, and cytosolic NADPH flux
(ME1, 0.6 mmol/liter-cell/h) would not account for the
required high level of NADPH flux. A recent elegant study (51)
suggested that in some cancers folate metabolism is the largest
source of NADPH. Based on these data (52), we estimated that
the serine-glycine one-carbon metabolism pathway cannot
account for the required NADPH consumption. In the light of
our 13C NMR lactate labeling data, the oxidative branch of the
PPP is the main source of NADPH in these cancer cells (6.6
mmol/liter-cell/h). This constitutes 80% in agreement with
the NADPH consumption rate during fatty acid biosynthesis.
Thus, the flux through the oxidative PPP appears to be 80%
sufficient to supply all of the NADPH required for fatty acid
production and is the main supplier of reducing equivalents in
DB-1 melanoma. A 20% difference in the rates of NADPH pro-
duction and consumption indicates that alternative sources of
NADP reduction, considered above, need to be taken into
account. We also found that mitochondrial pyruvate-malate
cycling was very high (4.3 mmol/liter-cell/h). This could also
contribute to defense against reactive oxygen species by pro-
ducing sufficient NADPH via ME3.
In summary, we have validated a novel method, bonded
cumomer analysis, for determining fluxes through specific
pathways of tumor energy metabolism. This method can be
applied to studies of perfused tumor cells in bioreactors or, with
some modifications, to in vivo studies for non-invasive investi-
gation of the metabolism of tumors in animals or humans. The
transition from isolated cells to in vivo rodent models and
humans is not simple and seamless, but it is feasible. The inter-
ested reader experienced in metabolic modeling might pursue
similar objectives using the methods outlined in this study
together with mathematical methods and metabolic models
referenced herein (53).
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